EUVIMEDEUVIMED entdecken
Crossref

Antimicrobial-resistant Pseudomonas aeruginosa in the USA: implications of a national surveillance gap

Richard R Watkins, Tracy L Lemonovich, Robert A Bonomo iD

Journal of Antimicrobial Chemotherapy · 03.11.2026 · 81 (12)

DOI: 10.1093/jac/dkag382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 05.11.2026. Verfasst von Richard R Watkins und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Northeast Ohio Medical University, Rootstown, OH, USA. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Pseudomonas Infections, Drug Resistance, Multiple, Bacterial, Anti-Bacterial Agents. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Surveillance data for Pseudomonas aeruginosa in the USA are distributed across systems designed for different purposes, potentially limiting standardized national surveillance of high-priority resistant phenotypes. We evaluated whether the Centers for Disease Control and Prevention (CDC) National Notifiable Diseases Surveillance System (NNDSS) can support surveillance of multidrug-resistant (MDR) P. aeruginosa and synthesized available CDC surveillance data to characterize the residual surveillance gap.

Methods

We reviewed the 2026 NNDSS list of nationally notifiable conditions for P. aeruginosa. Because neither P. aeruginosa infection nor a resistant phenotype was present, NNDSS case counts were unable to be analysed. We therefore conducted a descriptive secondary analysis of CDC National Healthcare Safety Network (NHSN) reports for 2018–21 and the 2022 NHSN Antimicrobial Resistance (AR) Option report.

Results

In 2018–21 adult NHSN data, 11.9% of tested P. aeruginosa isolates from device-associated infections were MDR, compared with 3.9% from surgical-site infections. Among central-line-associated bloodstream infection isolates, MDR proportions were highest in long-term acute-care hospitals (LTACHs, 25.3%), followed by hospital intensive-care units (14.2%), hospital wards (11.9%) and oncology units (8.5%). Among catheter-associated urinary tract infection isolates, MDR phenotype was observed in 20.8% of LTACH isolates. In the 2022 AR Option report, carbapenem non-susceptibility exceeded 10% among community-onset isolates and approached 20% among hospital-onset isolates.

Conclusions

NNDSS cannot currently quantify the burden of MDR P. aeruginosa, but substantial resistance surveillance is available through NHSN and the CDC AR Laboratory Network. The principal gap is not an absence of surveillance data but fragmentation across systems with different populations, denominators, objectives and reporting mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaPseudomonas InfectionsDrug Resistance, Multiple, BacterialAnti-Bacterial AgentsUnited StatesHumansCenters for Disease Control and Prevention, U.S.Cross InfectionEpidemiological MonitoringMicrobial Sensitivity TestsCatheter-Related Infections

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Northeast Ohio Medical University, Rootstown, OH, USA.
  • Clinical and Translational Science Collaborative, Case Western Reserve University, Cleveland, OH, USA.
  • Division of Infectious Diseases, MetroHealth Medical Center, Cleveland, OH, USA.
  • Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
  • Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA.
  • Departments of Medicine, Molecular Biology and Microbiology, Pharmacology, Biochemistry, Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

ORCID-Profile: Robert A Bonomo

Zitieren

APA

Watkins, R. R., Lemonovich, T. L., & Bonomo, R. A. (2026). Antimicrobial-resistant Pseudomonas aeruginosa in the USA: implications of a national surveillance gap. Journal of Antimicrobial Chemotherapy, 81(12). https://doi.org/10.1093/jac/dkag382

Vancouver

Watkins RR, Lemonovich TL, Bonomo RA. Antimicrobial-resistant Pseudomonas aeruginosa in the USA: implications of a national surveillance gap. Journal of Antimicrobial Chemotherapy. 2026;81(12). doi:10.1093/jac/dkag382

BibTeX
@article{Watkins2026,
  author = {Watkins, Richard R and Lemonovich, Tracy L and Bonomo, Robert A},
  title = {Antimicrobial-resistant Pseudomonas aeruginosa in the USA: implications of a national surveillance gap},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {12},
  doi = {10.1093/jac/dkag382}
}
Kostenlos starten →